NYSE American - Nasdaq Real Time Price ? USD Impact BioMedical Inc. (IBO) Follow Compare 2.5100 -0.3000 (-10.68%) At close: 4:00 PM EST 2.6100 +0.10 (+3.98%) After hours: 4:37 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker? Technology Targeting Inflammatory Disease HOUSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE: IBO), is thrilled to announce a significant milestone in its innovative Linebacker? technology platform. The Canadian Intellectual Property Office has issued Canadian Patent #3,024,728 entitled “Electrophilically Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders". This patent includes claims to novel enhanced phenolic compounds and pharmaceutical compositions as well as their uses in treat GlobeNewswire ? 30 days ago IBO -10.68% Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates HOUSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, is pleased to announce the successful completion of its Initial Public Offering (IPO). Notable is that over 30% of the IPO was purchased by existing investors which further demonstrates strong belief in the company and its potential. Frank D. Heuszel, CEO of Impact BioMedical, commented, "Th GlobeNewswire ? last month IBO -10.68% Impact BioMedical Inc. (NYSE: IBO) Announces 3F? US Patent Issue HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (“IBO”) is pleased to announce that the US Patent and Trademark Office has issued U.S. Patent No. 11,985,973 entitled “Insect Repelling Composition” developed within IBO’s 3F? technology platform. This is in addition to IBO’s prior granted U.S. Patent No. 11,246,310. Both patents include compositions and formulations of constituents found in plants and fragrances produced by plants, which, when applied as a natural insect repelle GlobeNewswire ? last month IBO -10.68% Impact BioMedical Inc. Introduces Leadership Team to Drive Innovation and Growth NEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting unique healthcare solutions, is pleased to introduce its executive leadership team, poised to lead the company through its next phase of innovation and growth. “We are excited to introduce our exceptional leadership team, which brings together a wealth of experience and a shared vision for driving innovation and growth at GlobeNewswire ? last month IBO -10.68% Impact BioMedical Inc. Announces the Closing of its Initial Public Offering NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a company discovering and developing new offerings in human healthcare and wellness, today announced the closing of its previously announced initial public offering of 1,500,000 shares of its common stock at a public offering price of $3.00 per share. The shares began trading on the NYSE American Market on September 16, 2024, under the ticker symbol “IBO”. In addition, Impact has granted the underwriters a GlobeNewswire ? last month IBO -10.68% DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a dedicated supporter and investor in Impact BioMedical Inc. (NYSE American: IBO), is delighted to announce the successful pricing of Impact BioMedical's initial public offering (IPO). Impact BioMedical, a trailblazer in advancing human healthcare and wellness solutions, has set its IPO price at $3.00 per share, with an initial offering of 1,500,000 shares. Trading under the ticker symbol “IBO,” these shares will begin GlobeNewswire ? last month DSS IBO -10.68% Impact BioMedical Inc. Announces Pricing of Initial Public Offering NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a company discovering and developing new offerings in human healthcare and wellness today announced the pricing of its initial public offering of 1,500,000 shares of its common stock at a public offering price of $3.00 per share. The shares are expected to begin trading on the NYSE American Market on September 16, 2024, under the ticker symbol “IBO.” The offering is expected to close on September 17, 2024, GlobeNewswire ? last month IBO -10.68% Performance Overview Trailing total returns as of 11/14/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return IBO S&P 500 YTD -16.33% +5.61% 1-Year -16.33% +5.61% 3-Year -16.33% +5.61%
